CCNE1 is known to be amplified and operative as a cancer gene in serous ovarian cancer 27, and the breakpoints in TSHZ3 could be collateral to amplification involving CCNE1. To further evaluate this, those TMA cases with TSHZ3 breakpoints and available DNA (n = 10) were evaluated using Affymetrix SNP 6.0 gene arrays for evidence of independence from CCNE1 amplification. This evidence concerns the gene CCNE1 and ovarian serous adenocarcinoma.